| Welcome
to the 16th issue of PharmaView!
Pharmaceutical Marketers
are facing increasing pressures: increasing competition; squeezed
margins; shrinking budgets; more to do and less time to do it. It’s
becoming difficult to work any harder, and of course it's always
better to work smarter. Therefore we bring you the PharmaView.
PharmaView is a biweekly
educational and informative newsletter for improving readers’
marketing knowledge and reporting the latest news in the pharma
industry. It also provides great opportunities to exchange ideas,
network and be recognized among your peers in the
industry.
Through PharmaView, you can:
Learn peer’s experience
in pharma marketing
Stay in touch with what’s
happening in pharmaceutical marketing today
Be on the pioneering edge
of pharmaceutical marketing
Have networking / idea
exchange opportunities
 About
Us
Integrating local knowledge with international
perspective, Consultech Co. Ltd. offers its clients and
prospects one-lstop solutions with sales and marketing consultancy,
advertising and promotion strategies.
Consultech is an
affiliate company of Omnicom, the world's largest advertising and communications holding company.
Creative Design: Case Study of
Ephydrol
Visuals
Glaxo Gives High-Five to Cancer Market
After months of working damage
control for Avandia, GlaxoSmithKline has released some positive news
on the oncology front. The company announced last Monday that it
plans to release five new cancer medicines over the next three
years, a huge leap for a company whose name is not synonymous with
that space.
Jun 27, 2007
FDA Approves First
Molecular-Based Lab Test to Detect Metastatic Breast Cancer
The U.S. Food and Drug
Administration today approved the first molecular-based laboratory
test for detecting whether breast cancer has spread (metastasized)
to nearby lymph nodes. The GeneSearch BLN Assay detects molecules
that are abundant in breast tissue but scarce in a normal lymph
node.
Jul 16,
2007
Merck Serono's Fertility
Treatment Pergoveris Approved in European Union
Merck Serono S.A. announced today
that the European Commission has granted a marketing authorization
for Pergoveris(tm) intended for the stimulation of follicular
development in women with severe luteinizing hormone (LH) and
follicle stimulating hormone (FSH) deficiency.
Jun 29, 2007
Novartis Corporation 's
Exforge(R) Receives Final US Approval as New and Powerful Treatment
Option for Patients With High Blood Pressure
Exforge®, a single-l tablet
combination of two of the most prescribed high blood pressure
medicines, has been granted final US Food and Drug Administration
approval and is expected to be available soon as an effective
treatment option for millions in the US who suffer from high blood
pressure.
Jun. 21, 2007
Feedback loop
New technology is making
closed-loop marketing more effective and creating a stronger
connection between sales and marketing through real-time feedback
from physicians.
Jun.
2007
Pharma Seeing Double, Says New Report
PricewaterhouseCoopers' recent
announcement that the global pharma market will double to $1.3
trillion by 2020 should have been met with corks popping and
confetti falling.
Jun 27, 2007
Direct-to-Consumer (DTC)
Marketing for U.S. Prescription Drugs Moves Online, Cegedim Dendrite
Survey Says
The U.S. pharmaceutical industry
is embracing online media to build relationships with consumers and
is cutting back on traditional broadcast and print media to promote
drugs, according to Cegedim Dendrite's latest DTC Industry Check-Up
Survey.
Jul 13, 2007
Diabetes Drug Has Good Results In
Long Trial
Many patients treated with
Byetta, a diabetes drug by Amylin Pharmaceuticals Inc. and Eli Lilly
& Co., were able to maintain good blood-sugar control and also lose
weight after three years on the drug, according to a study.
Jun 26, 2007
Bristol, Glaxo diabetes drugs test new concept
Drugmakers are working on
experimental diabetes drugs using a novel mechanism to help flush
excess blood sugar out of the body, according to results of small
studies presented at a medical meeting on Sunday.
Jun 24, 2007
IBM Signs $1.4 Billion Global
Strategic Outsourcing Agreement With AstraZeneca
IBM today announced that they
have signed a $1.4 billion, seven-year global strategic outsourcing
agreement with AstraZeneca. The agreement renews and expands on the
scope of an existing contract and covers the provision of IT
infrastructure services to 60 countries. It includes services to
additional functions within AstraZeneca, one of the world's largest
pharmaceutical companies.
Jul 16, 2007
Please feel free to offer your opinions and advices about
PharmaView in order to better our services. Should you have any
comments, or if you want to unsubscribe from PharmaView,
please send us an email:
pharmaview@Consultech.com.cn . Thank
you!
| 
